Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Talala, K.
56  Ergebnisse:
Personensuche X
?
1

Statin use and outcomes of oncological treatment for castra..:

Peltomaa, A. I. ; Talala, K. ; Taari, K....
Scientific Reports.  13 (2023)  1 - p. , 2023
Link: https://doi.org/10.1038/..
 
?
2

Causal modeling to unravel the screening effect in ERSPC: S..:

Remmers, S. ; Talala, K. ; Arnsrud-Godtman, R....
European Urology.  83 (2023)  - p. S1271-S1272 , 2023
Link: https://doi.org/10.1016/..
 
?
3

Prostate cancer prognosis after initiation of androgen depr..:

Peltomaa, A. I. ; Raittinen, P. ; Talala, K....
Prostate Cancer and Prostatic Diseases.  24 (2021)  3 - p. 917-924 , 2021
Link: https://doi.org/10.1038/..
 
?
4

Outcomes of prostate cancer screening among men using antid..:

Vettenranta, A. ; Murtola, T. J. ; Talala, K....
Scientific Reports.  11 (2021)  1 - p. , 2021
Link: https://doi.org/10.1038/..
 
?
5

Antihypertensive drugs and prostate cancer risk in a Finnis..:

Siltari, A. ; Murtola, T.J. ; Talala, K....
European Urology Supplements.  18 (2019)  1 - p. e1815 , 2019
Link: https://doi.org/10.1016/..
 
?
6

Effects of antihypertensive drug use on prostate cancer-spe..:

Siltari, A. ; Murtola, T. ; Talala, K....
European Urology Supplements.  18 (2019)  1 - p. e1533 , 2019
Link: https://doi.org/10.1016/..
 
?
7

Anticoagulants and cancer mortality in the Finnish randomiz..:

Kinnunen, P. T. T. ; Murtola, T. J. ; Talala, K....
Cancer Causes & Control.  30 (2019)  8 - p. 877-888 , 2019
Link: https://www.jstor.org/st..
 
?
8

Anticoagulants and cancer mortality in the Finnish randomiz..:

Kinnunen, P. T. T. ; Murtola, T. J. ; Talala, K....
Cancer Causes & Control.  30 (2019)  8 - p. 877-888 , 2019
Link: https://doi.org/10.1007/..
 
?
9

Prostate cancer prognosis after initiation of androgen depr..:

Peltomaa, A.I.P. ; Talala, K. ; Taari, K....
European Urology Supplements.  18 (2019)  1 - p. e1398 , 2019
Link: https://doi.org/10.1016/..
 
?
10

Antidiabetic drugs and risk of benign prostatic hyperplasia:

Nygård, L. ; Talala, K. ; Taari, K....
European Urology Supplements.  17 (2018)  2 - p. e1594 , 2018
Link: https://doi.org/10.1016/..
 
?
11

Allopurinol and risk of benign prostatic hyperplasia in a F..:

Kukko, V. ; Kaipia, A. ; Talala, K....
European Urology Supplements.  17 (2018)  2 - p. e1589 , 2018
Link: https://doi.org/10.1016/..
 
?
12

Blood glucose balance and disease-specific survival after p..:

Murtola, T. ; Sälli, S. ; Talala, K....
European Urology Supplements.  17 (2018)  2 - p. e378 , 2018
Link: https://doi.org/10.1016/..
 
?
13

Outcomes of PSA-based prostate cancer screening among men u..:

Murtola, T. ; Vettenranta, A. ; Talala, K....
European Urology Supplements.  16 (2017)  3 - p. e424 , 2017
Link: https://doi.org/10.1016/..
 
?
14

The effect of non-steroidal anti-inflammatory drugs on risk..:

Murtola, T. ; Nygård, L. ; Talala, K....
European Urology Supplements.  16 (2017)  3 - p. e935 , 2017
Link: https://doi.org/10.1016/..
 
?
15

776 Prostate cancer incidence and cardiovascular mortality ..:

Murtola, T. ; Rytkönen, J. ; Talala, K....
European Urology Supplements.  15 (2016)  3 - p. e776 , 2016
Link: https://doi.org/10.1016/..
 
1-15